<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39364390</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2590-1362</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Vaccine: X</Title><ISOAbbreviation>Vaccine X</ISOAbbreviation></Journal><ArticleTitle>Enhanced production of recombinant coxsackievirus A16 using a serum-free HEK293A suspension culture system for bivalent enterovirus vaccine development.</ArticleTitle><Pagination><StartPage>100559</StartPage><MedlinePgn>100559</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100559</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvacx.2024.100559</ELocationID><Abstract><AbstractText>Coxsackievirus A16 (CVA16) is one of the primary pathogens that causes hand, foot, and mouth disease (HFMD) in young children. In previous studies, CVA16 vaccine development has encountered several challenges, such as inefficient replication of the CVA16 virus in present culture systems, the induction of only mild neutralizing antibody titers, and neutralizing antibodies induced by certain vaccine candidates that are unable to protect against CVA16 viral challenge. In this study, we constructed a DNA-launched CVA16 infectious clone (CVA16ic) based on the genomic sequence of the CVA16 N5079 strain to minimize interference from viral quasispecies. The biochemical properties of this CVA16ic strain were similar to those of its parental strain. Serum-free HEK293A suspension cells, which produced higher virus titers than Vero cells, were demonstrated to improve CVA16 production yields. In addition, our study showed that inactivated EV-A71 antigens could enhance the immunogenicity of inactivated CVA16 mature/full particles (F-particles), suggesting that a bivalent CVA16 and EV-A71 vaccine may be an effective strategy for CVA16 vaccine development. These findings are expected to provide novel strategies and accelerate the development of bivalent HFMD vaccines.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-An</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yu-Sheng</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Chih-Yeu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Ting-Ting</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>School of Dentistry &amp; Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shang-Rung</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>School of Dentistry &amp; Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen-Ren</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vaccine X</MedlineTA><NlmUniqueID>101748769</NlmUniqueID><ISSNLinking>2590-1362</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bivalent vaccine</Keyword><Keyword MajorTopicYN="N">Coxsackievirus A16 (CVA16)</Keyword><Keyword MajorTopicYN="N">DNA-launched infectious clone</Keyword><Keyword MajorTopicYN="N">Hand, foot, and mouth disease (HFMD)</Keyword><Keyword MajorTopicYN="N">Inactivated whole virion vaccine</Keyword><Keyword MajorTopicYN="N">Serum-free HEK293A suspension culture</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364390</ArticleId><ArticleId IdType="pmc">PMC11447303</ArticleId><ArticleId IdType="doi">10.1016/j.jvacx.2024.100559</ArticleId><ArticleId IdType="pii">S2590-1362(24)00132-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., et al. Coxsackievirus A16: Epidemiology, diagnosis and vaccine. Hum Vaccin Immunother. 2014;10:360–367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M., Chong P. Is a multivalent hand, foot, and mouth disease vaccine feasible? Hum Vaccin Immunother. 2015;11:2688–2704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4685682</ArticleId><ArticleId IdType="pubmed">26009802</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C.Y., Liu C.C. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccines. 2018;17:819–831.</Citation><ArticleIdList><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C.Y., Liu C.C. Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies. Expert Opin Drug Discov. 2022;17:27–39.</Citation><ArticleIdList><ArticleId IdType="pubmed">34382876</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Guo M.S., Lin F.H., Hsiao K.N., Weng S.Y., Chou A.H., et al. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS One. 2012;7:e49973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511423</ArticleId><ArticleId IdType="pubmed">23226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Yan K., Feng Y., Huang X., Ku Z., Cai Y., et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30:6642–6648.</Citation><ArticleIdList><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Liu Q., Huang X., Li D., Ku Z., Zhang Y., et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine. 2013;31:2215–2221.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499596</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E., Cheng C., Zhang Y., Wang J., Che Y., Pu J., et al. Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccin Immunother. 2014;10:1266–1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4896597</ArticleId><ArticleId IdType="pubmed">24583556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.W., Liu C.C., Lu T.C., Liu S.J., Chow Y.H., Chong P., et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. Biomed Res Int. 2014;2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4071850</ArticleId><ArticleId IdType="pubmed">25006583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S., Jiang L., Liang Z., Mao Q., Su W., Zhang H., et al. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice. Hum Vaccin Immunother. 2014;10:2885–2895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5443096</ArticleId><ArticleId IdType="pubmed">25483672</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T., Xie T., Li H., Song X., Yue L., Wang X., et al. Immune responses of a CV-A16 live attenuated candidate strain and its protective effects in rhesus monkeys. Emerg Microbes Infect. 2020;9:2136–2146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7580583</ArticleId><ArticleId IdType="pubmed">32930072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Zhang Y., Zhang X., Hu Y., Dong C., Liu L., et al. Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques. Virology. 2017;500:198–208.</Citation><ArticleIdList><ArticleId IdType="pubmed">27829175</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X., Mao Q., Li Y., Hao C., Bian L., Chen P., et al. Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo. Hum Vaccin Immunother. 2018;14:1275–1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989894</ArticleId><ArticleId IdType="pubmed">29337652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lien S.C., Shen Y.S., Lin H.Y., Wu S.R., Fang C.Y., Chen C.H., et al. Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system. Virus Res. 2023;329</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10194310</ArticleId><ArticleId IdType="pubmed">36958398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray M., Lai C.J. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci USA. 1991;88(22):10342–10346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52924</ArticleId><ArticleId IdType="pubmed">1682924</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann G., Fujii K., Kino Y., Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci USA. 2005;102:16825–16829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283806</ArticleId><ArticleId IdType="pubmed">16267134</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y.T., Chow Y.H., Hsiao K.N., Hu K.C., Chiang J.R., Wu S.C., et al. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology. Antiviral Res. 2016;132:225–232.</Citation><ArticleIdList><ArticleId IdType="pubmed">27387826</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X., Muruato A., Lokugamage K.G., Narayanan K., Zhang X., Zou J., et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe. 2020;27:841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153529</ArticleId><ArticleId IdType="pubmed">32289263</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogales A., Martínez-Sobrido L. Reverse Genetics Approaches for the Development of Influenza Vaccines. Int J Mol Sci. 2016;18:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5297655</ArticleId><ArticleId IdType="pubmed">28025504</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Liu Q., Cai Y., Leng Q., Huang Z. Construction and characterization of an infectious clone of coxsackievirus A16. Virol J. 2011;8:534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3283524</ArticleId><ArticleId IdType="pubmed">22165961</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C., Li X., Liu S., Xu L., Ye H., Qin C.F., et al. Development and characterization of a clinical strain of Coxsackievirus A16 and an eGFP infectious clone. Virol Sin. 2015;30:269–276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8200862</ArticleId><ArticleId IdType="pubmed">26220729</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Liu X., Wang S., Li J., Hou M., Liu G., et al. Identification of a nucleotide in 5' untranslated region contributing to virus replication and virulence of Coxsackievirus A16. Sci Rep. 2016;6:20839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748407</ArticleId><ArticleId IdType="pubmed">26861413</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Shen C., Chen T., Lan K., Huang Z., Zhang Y., et al. Improved plasmid-based recovery of coxsackievirus A16 infectious clone driven by human RNA polymerase I promoter. Virol Sin. 2016;31:339–341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193394</ArticleId><ArticleId IdType="pubmed">27113242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu R., Wang M., Liu L., Yan J., Fan J., Li X., et al. The development and characterization of a stable Coxsackievirus A16 infectious clone with Nanoluc reporter gene. Front Microbiol. 2023;13:1101850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9871592</ArticleId><ArticleId IdType="pubmed">36704559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu R., Li X., Zhang P., Xu M., Zhao J., Yan J., et al. Integration of HiBiT into enteroviruses: A universal tool for advancing enterovirus virology research. Virol Sin. 2024;39:422–433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11279724</ArticleId><ArticleId IdType="pubmed">38499155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer K.B., Borrow R., Blanchard T.J. Multivalent and Multipathogen Viral Vector Vaccines. Clin Vaccine Immunol. 2017;24:e00298–e00316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216423</ArticleId><ArticleId IdType="pubmed">27535837</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang J.Y., Jiang R., Hsieh Y.C., Tsao A., et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One. 2013;8:e79783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Chow Y.H., Chong P., Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine. 2014;32:6177–6182.</Citation><ArticleIdList><ArticleId IdType="pubmed">25218294</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine E.A., Fuchs J., Das S.C., Partidos C.D., Osorio J.E. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice. Viruses. 2015;7(11):5919–5932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664989</ArticleId><ArticleId IdType="pubmed">26593938</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Guo M.S., Wu S.R., Lin H.Y., Yang Y.T., Liu W.C., et al. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58–66.</Citation><ArticleIdList><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhang Y., Li H., Liu L. Hand-Foot-and-Mouth Disease-Associated Enterovirus and the Development of Multivalent HFMD Vaccines. Int J Mol Sci. 2022;24:169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9820767</ArticleId><ArticleId IdType="pubmed">36613612</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y.S., Chow Y.H., Fang C.Y., Wu S.R., Chen C.H., Huang M.H., et al. The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage. J Microbiol Immunol Infect. 2023;56:1121–1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">37919172</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Sheldon J., Perales C. Viral quasispecies evolution. Microbiol Mol Biol Rev. 2012;76:159–216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372249</ArticleId><ArticleId IdType="pubmed">22688811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sène M.A., Kiesslich S., Djambazian H., Ragoussis J., Xia Y., Kamen A.A. Haplotype-resolved de novo assembly of the Vero cell line genome. npj Vaccines. 2021;6:106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8379168</ArticleId><ArticleId IdType="pubmed">34417462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiesslich S., Kamen A.A. Vero cell upstream bioprocess development for the production of viral vectors and vaccines. Biotechnol Adv. 2020;44</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405825</ArticleId><ArticleId IdType="pubmed">32768520</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont J., Euwart D., Mei B., Estes S., Kshirsagar R. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2016;36:1110–1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5152558</ArticleId><ArticleId IdType="pubmed">26383226</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385:2348–2360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhu M., Fang Y., Rong H., Gao L., Liao Q., et al. Bioinformatics-based prediction of conformational epitopes for Enterovirus A71 and Coxsackievirus A16. Sci Rep. 2021;11:5701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7952546</ArticleId><ArticleId IdType="pubmed">33707530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y.S., Xia Y., Xu F., Lu H.J., Mao Z.A., Gao M., et al. Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils. Emerg Microbes Infect. 2022;11:1994–2006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377242</ArticleId><ArticleId IdType="pubmed">35787233</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi E.J., Kim Y.I., Song J.H., Ko H.J., Ahn S.H., Lee H.J., et al. Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease. Vaccine. 2023;41:6055–6063.</Citation><ArticleIdList><ArticleId IdType="pubmed">37648607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>